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MC Donnelly, PC Hayes, KJ Simpson 
Dept. of Hepatology, Division of Clinical and Surgical Sciences, University of Edinburgh 
and Scottish Liver Transplantation Unit, Royal Infirmary of Edinburgh, EDINBURGH. 
EH16 4SA United Kingdom. 
Abstract 
The etiology and outcomes of acute liver failure have changed since the definition of this 
disease entity in the 1970s. In particular, the role of emergency liver transplantation has 
evolved over time, with the development of prognostic scoring systems to facilitate listing of 
appropriate patients, and a better understanding of transplant benefit in patients with acute 
liver failure. This review examines the changing etiology of acute liver failure, transplant 
benefit, outcomes following transplantation and future alternatives to emergency liver 
transplantation in this devastating condition. 
Introduction 
Acute liver failure (ALF) is a rare condition resulting from the sudden loss of hepatic 
parenchyma and metabolic function. In the United States, ALF is estimated to affect 2000 
people per year
1, 2
, with the incidence in the United Kingdom reported at 1-8 per million 
population
3
. Incidence in the developing world may be higher, but data are lacking. ALF was 
originally considered a fatal disease. However, around 60-75% of patients should now be 
expected to survive due to increased utilization of emergency orthotopic liver transplantation 
(OLT) and improved medical and intensive care management 
4, 5
. ALF is an uncommon 
indication for OLT, accounting for 8% of all liver transplants carried out in Europe between 
1988-2009
6
, and 3.9% of listings for OLT in the US between 1995-2005
7
. Utilization of OLT 
is limited by accurate and timely identification of appropriate patients, the development of 
contraindications on the waiting list and the unavailability of a graft. In this review article we 
discuss the current challenges in the field of liver transplantation for ALF, suggesting future 
directions for research and clinical work. 
Defining ALF 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/lt.24403
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Trey and Davidson
8
 originally defined the condition in the early 1970s as the development of 
hepatic encephalopathy (HE) and coagulopathy in the setting of an acute liver injury, in the 
absence of chronic liver disease (CLD). Subsequently, several revised definitions have been 
suggested. A recent systematic review
9
 highlighted the heterogeneity of current definitions of 
ALF in the literature: 41 separate definitions of ALF had been used in 87 different studies. 
The main components accounting for the differences included the presence and/or grade of 
HE, interval between onset of symptoms or jaundice and development of HE, the severity of 
coagulopathy and the occurrence of pre-existing liver disease. No definitive consensus exists, 
although most studies would consider an INR >1.5 to represent coagulopathy and any grade 
of encephalopathy to represent ALF. There is a real need for unifying diagnostic criteria for 
ALF to facilitate a consistent approach to the clinical management of ALF and related 
research. Consensus on the definition of ALF and ensuring its universal application would be 
a first step to improving generalisation of clinical research into this rare condition.  
HE is usually considered the defining clinical feature of ALF, differentiating cases from those 
with acute liver injury (ALI). Patients with ALI have sudden, significant liver injury and 
coagulopathy but no HE. In the US, patients with ALF are listed for urgent transplantation on 
meeting the United Network for Organ Sharing (UNOS) Status 1a listing criteria for ALF
10
. 
To assign an adult Status 1a, the presence of HE is a prerequisite. However, pediatric cases 
can be listed without developing HE
2
. In addition, some patients with certain causes of ALI 
develop HE late in their clinical course. In such cases, HE is often precipitated by bacterial 
infection which precludes or delays OLT. Some have argued for listing these patients prior to 
the development of HE
11
. In the UK, criteria for ALF super-urgent listing have recently been 
updated
12
 allowing listing of patients with unfavorable non-acetaminophen (non-APAP) 
etiologies (such as those with indeterminate ALF or drug induced liver injury (DILI)) in the 
absence of HE if the following criteria are met: INR >2 after vitamin K repletion plus any 
two of; age >40 or <10 years, prothrombin time >50seconds or INR >3.5, or bilirubin 
>300umol/L (Table 1). These changes are the subject of on-going audit and would also 
require further assessment and validation in other centres.  
Changing etiology of disease 
There are worldwide geographical differences in etiology of ALF. Hepatotrophic viruses 
(particularly hepatitis B and E) are the most common cause of ALF in developing countries, 
compared with drugs e.g. acetaminophen (APAP) in the developed world. Such differences in 
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etiology result from a combination of factors, including endemic presence of hepatitis viruses 
in the East, cultural differences (e.g. self-medication with APAP is rare in the east) and 
genetic differences in susceptibility to conditions such as acute fatty liver of pregnancy 
(AFLP)
13
 and APAP overdose
14
.  
In 14-20% of patients with ALF, no identifiable cause is found after exclusion of all other 
potential etiologies by the appropriate investigations
15
. The terminology for ALF without an 
identifiable cause has evolved over time. Initially, this disease entity was termed non-A, non-
B hepatitis, followed by non-A to E hepatitis. More recently, this syndrome has been labeled 
seronegative hepatitis or indeterminate ALF. For the purposes of this review, indeterminate 
ALF is the nomenclature of choice. Most cohort studies of ALF report a significant 
percentage of cases being due to indeterminate ALF, but it remains unclear if this is a distinct 
but yet unidentified single etiology. Introduction of alternative investigational methodology 
may reduce uncertainty in this group of patients. The US Acute Liver Failure Study Group 
(ALFSG) reported that using the APAP adduct test in a group of patients with indeterminate 
ALF identified occult APAP overdose in 18%
16
.  Further work is needed to explore the 
origins of this disease entity, and formulate and validate a definition that could be universally 
adopted.  
The many causes of ALF have different clinical courses, complications and prognoses and 
therefore need for OLT. In APAP overdose, ALF has a rapidly progressive course with 
increased risk of development of kidney injury and cerebral edema, however spontaneous 
survival rates are higher compared with other causes such as indeterminate cases and DILI. 
Therefore, difference in incidence of specific etiologies of ALF will influence the utilization 
of emergency OLT, in addition to the logistical provision of transplantation for such patients 
in different parts of the world.  
Some UK centers have reported a decline in both the total number of APAP related 
admissions and the severity of disease since the introduction of UK legislation restricting 
sales of APAP in 1998. A look back study from Kings College, London observed a 
significant decline in the number of APAP-ALF admissions during 1973-2008 and a 
reduction in the severity of disease
4
. In contrast, no significant change in the number of 
APAP admissions was observed in other parts of the UK although an increased frequency of 
staggered overdoses were reported, an overdose pattern associated with significantly lower 
spontaneous survival rates in this cohort
17
. A sales restriction on APAP has never been 
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introduced in the USA, where the percentage of ALF secondary to APAP has increased from 
28% in 1998 to 51% in 2003
14
. In a large multicenter US study 48% of APAP-ALF patients 
were admitted with an unintentional overdose (including unintentional multiple time point 
ingestion), however in this cohort mortality was not significantly related to overdose 
pattern
14
.  
With regards to other etiologies, the Kings group
4
 also reported a significant decline in the 
number of admissions with ALF secondary to viral hepatitis between 1973 and 2008. 
Reduced frequency of acute viral hepatitis may have resulted from improved public health 
measures, more effective and rapidly acting antiviral therapy in acute HBV infection and 
combined HAV/HBV vaccination. There was no significant change in the number of patients 
presenting with non-APAP related DILI or pregnancy related disease in the Kings cohort 
over time. An awareness of the changing etiology of ALF over time is important. The 
etiology of ALF is undoubtedly related to subsequent need for transplantation. However, in 
the King College look-back study the use of transplantation significantly increased over time 
despite the reduced frequency of APAP-ALF, with the proportion of patients transplanted 
being greater in the non-APAP versus APAP cohort
4
. 
Non-transplant management options 
N-acetylcysteine (NAC) has a proven evidence base in APAP poisoning, but there are 
relatively limited medical, non-transplant therapies available for non-APAP ALF. NAC can 
improve liver oxygenation and has antioxidant, anti-inflammatory and immunologic effects
18
. 
NAC also has beneficial hemodynamic effects and may improve cerebral perfusion 
pressure
19, 20
. Several studies have therefore investigated NAC therapy in non-APAP ALF. 
Lee et al
21
 undertook a prospective, multicenter, double-blind trial comparing intravenous 
(IV) NAC versus placebo in patients with non-APAP ALF. IV NAC improved transplant-free 
survival in patients with grade I or II HE but was ineffective in patients with advanced HE. A 
study undertaken in the pediatric non-APAP ALF population reported that use of NAC did 
not improve one-year survival
22
 and a meta-analysis of the efficacy and safety of NAC in 
adult non-APAP ALF reported no significant difference in overall survival between the NAC 
and control groups
23
. However, NAC may still have a role in specific non-APAP ALF 
etiologies, for example in the management of mushroom poisoning and DILI-ALF
24
. Possible 
non-transplant management options, including the role of the systemic inflammatory 
response and infection, are discussed individually in the supplemental material.  
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Assessing prognosis and listing for transplant 
Accurate prognostic models are vital to identify those patients who are most likely to benefit 
from emergency OLT, at a time when transplant is still feasible. Similarly, the timely 
prediction of patients likely to survive spontaneously prevents unnecessary OLT and long 
term immunosuppressant therapy. Lake previously reported that as many as 20% of patients 
with ALF may be transplanted unnecessarily
25
. A recent systematic review identified survival 
was 24% in non-transplanted APAP-ALF patients meeting the Kings College Hospital Poor 
Prognostic Criteria (KCC)
26
. Spontaneous survival rates have improved over time for many 
etiologies
4
; however prognostic models have not been adapted to account for this. There is a 
desperate need for better prognostic criteria to maximise the transplant benefit afforded to 
patients with ALF. 
Several prognostic scoring systems have been proposed, validated and reviewed in the 
literature. Unfortunately all of these models have shown inconsistencies in reproducibility 
and prognostic accuracy, limiting their clinical utility. This may at least in part be as a result 
of a heterogeneous patient population and the wide variety of definitions of ALF in such 
studies. A further problem lies in that many studies investigating prognostic models equate 
liver transplantation with death; this falsely elevates the positive predictive value of scoring 
systems. The most widely studied and utilized criteria are the KCC, Clichy criteria and Model 
for End-Stage Liver Disease (MELD). These are discussed in more detail in the 
supplementary material. 
Transplant benefit  
With studies demonstrating increasing spontaneous survival rates in some groups of patients 
with ALF, the survival benefit afforded by emergency OLT has been called into question. 
However, there are limited data available to facilitate this type of analysis. Many cohort 
studies do not report the outcomes of patients reaching poor prognostic criteria who are not 
transplanted or listed for OLT. Analysis is further complicated by the observations that after 
reaching poor prognostic criteria many patients are not considered transplant candidates due 
to medical or psychiatric contraindications, or they may be too sick to be offered emergency 
OLT. As many as 60% of APAP-ALF patients with poor prognostic criteria may be excluded 
from OLT due to contraindications compared with 23% in non-APAP ALF cases and 
consequently the mortality in the former group is increased
27
.  
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Most would accept that there is a clear survival advantage in patients with non-APAP ALF.  
Kremers assessed the survival benefit associated with transplant in a US cohort of patients 
with ALF listed under UNOS Status 1 criteria
28
. In patients with non-APAP ALF, OLT was 
significantly associated with improved survival, especially in patients with higher MELD 
scores. In the Scottish cohort overall survival in the non-APAP ALF group was 58.0%, with 
71.1% of surviving patients undergoing OLT
27
. In the Kings College cohort
4
, introduction of 
OLT had transformed the outcome for patients with non-APAP ALF, from 4.2% survival to 
hospital discharge in 1973-1978 to 67.6% in 2004-2008.  
In contrast, the survival advantage conferred by emergency OLT in APAP-ALF is less clear 
cut, and no formally reported analysis of the survival benefit with OLT in this cohort has 
been undertaken. In APAP-ALF, outcomes have improved in those patients undergoing 
transplantation and also in those who are managed medically
29
. O’Grady reports that the 
median time from listing to acceptance of an organ is 7.5 hours
29
, highlighting the importance 
of listing only appropriate patients in a timely fashion to prevent unnecessary transplantation. 
As previously noted, prognostic scoring systems have not been adapted to account for 
temporal changes in disease epidemiology. The Kings College group suggest that the survival 
advantage with emergency OLT in APAP-ALF may be as low as 14%
4
. In contrast a survival 
advantage analysis for the Scottish APAP-ALF cohort with KCC suggests that survival 
advantage in this cohort with high mortality is considerably higher
27
: survival in the patients 
who were not considered transplant candidates was 16.7% compared with 78.8% survival in 
APAP-ALF transplanted patients. However, approximately 50% of cases excluded from 
emergency OLT were considered too sick to transplant. Clearly other data from different 
cohorts stratified for disease severity are needed to define survival advantage in both APAP 
and non-APAP ALF.  
Contraindications to listing 
Prognostic scoring systems cannot and should not be used in isolation to identify those 
patients who could and should be listed for emergency OLT. Such information needs to be 
considered concurrently with the medical and psychiatric evaluation of the patient. 
Unfortunately time constraints truncate this process and HE can limit a patients input. In the 
UK, the National Health Service Blood and Transfusion (NHSBT) service provides a list of 
absolute and relative contraindications to liver transplant
30
. Concurrent medical or psychiatric 
co-morbidity are deemed relevant if they are severe enough to affect the patient’s prospect for 
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survival post-transplant or likelihood of compliance with medical therapy and outpatient 
clinic follow up. Medical contraindications include active sepsis, severe coexistent medical 
disease, progressive inotropic or ventilatory support or irreversible brain stem dysfunction. In 
terms of psycho-social disease, contraindications to transplantation include multiple previous 
episodes of self harm (>5), refractory or resistant mental illness, active intravenous drug use 
or polydrug or alcohol use in a severe and chaotic fashion and a consistently stated wish to 
die in the absence of established mental illness. In particular, predicting compliance with the 
intensive post-transplant immunosuppression and follow up regimen in those patients with 
psychiatric co-morbidity can be very difficult to assess within the time constraints available 
to assess the patient with ALF.  
Keeping patients alive on the transplant waiting list 
In view of significantly reduced survival time, patients with ALF are usually afforded priority 
for donated liver allocation in most countries. The US-ALF study group reported a median 
time from listing to transplant of one day
2 
and Ichai reported a median listing to transplant 
time of 7.5 hours
31
. Despite this exceptional access to transplantation, the mortality of listed 
patients with ALF remains very high. A study from Kings College reported a 92% mortality 
rate of patients on the waiting list who did not receive a liver transplant
32
. In a large US 
study, 25% of all patients listed for transplantation for ALF died whilst awaiting a suitable 
graft
15
. In the Scottish cohort mortality on the transplant waiting list was higher in the APAP-
ALF group (31.8%) compared with the non-APAP ALF group (15.7%)
27
. Ichai reported that 
13.5% of patients listed for super-urgent OLT in France died or left the waiting list due to 
clinical deterioration
31
. The Kings College group report a significantly higher percentage of 
patients dying on the waiting list compared with the US and France, and this may be related 
to the higher percentage of patients listed with APAP-ALF. The Kings group also identified 
that in their cohort, a vasopressor requirement at time of listing was associated with a higher 
risk of failure to transplant and it is possible that this reflects listing of a sicker group of 
patients.  
Keeping patients alive while awaiting a suitable donor organ is a significant challenge in the 
management of ALF. Critical care involvement is crucial. The intensive care management of 
these patients is complex and challenging. Although several guidelines exist
24, 33
, much 
remains to be determined with regards to the best evidence-based practice. ALF patients may 
develop overwhelming sepsis, multi-organ failure or irreversible cerebral edema with raised 
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intracranial pressure (ICP). Improvements in managing the ALF patient whilst awaiting a 
suitable graft include developments in renal support with a shift from using hemodialysis to 
continuous veno-venous hemofiltration (CVVH), and in particular, a better understanding of 
the pathogenesis and management of cerebral edema and raised intracranial pressure (ICP) in 
ALF which is discussed in more detail in the supplementary material.  
De-listing  
Clearly, if a patient’s condition deteriorates such that the outcome post-transplant was 
deemed futile, then that patient should be removed from the waiting list. However, futility is 
a vaguely defined concept and at present there are no validated criteria to assist in the 
decision making process. O’Grady has proposed a list of factors which might be utilized 
when deciding to proceed with transplant, when to pause and consider the benefit, and when 
to abandon the planned transplant
34
. ‘Pausing’ is suggested when patients show sustained 
improvement of prognostic criteria without general clinical deterioration, in those with 
APAP-ALF who do not have grade 3-4 HE or in whom severe acidosis or elevated lactate 
responds rapidly to resuscitation, and if the allocated graft is considered ‘marginal.’ 
Situations in which the planned transplant might be abandoned include rapidly escalating 
inotrope requirements, invasive fungal infection and objective evidence of brainstem death. 
Untreated infection or progressive infection despite 48 hours of appropriate antimicrobial 
therapy and clinically significant ARDS (Fi02 >0.8) should also be considered a 
contraindication to transplant. Validated criteria assessing futility would be an extremely 
useful clinical tool. However until these are available individual decisions will continue to be 
made depending upon expert bedside assessment and dynamic clinical data.  
Currently, no data or prediction models exist to facilitate clinical decision making in delisting 
patients because of clinical improvement. Potential delisting criteria in the setting of clinical 
improvement might include; reversal of HE, weaning from vasopressor support and recovery 
of renal function
11
. Timely delisting (when appropriate) should be considered equally as 
important in the patients clinical course as timely listing, to ensure maximum patient benefit 
and appropriate utilization of scarce donor organs. 
Post-operative outcomes 
Immediate outcomes after emergency OLT for ALF are improving, but have not yet reached 
those reported following elective OLT. Liver transplantation for ALF is characterised by a 
relatively high early post-operative mortality, with the majority of deaths occurring in the 
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first 90 days after transplant
35
. For patients transplanted for ALF, 90-day mortality was 
higher in the UK (24.9%) versus the US (18.2%), and was higher than that reported with 
patients transplanted for CLD (UK 9.4% versus US 8.0%)
36
. Data from the European Liver 
Transplant Registry reported that 1-year survival for ALF after OLT is around 10% lower 
than that for elective transplantation
35
. However, overall outcomes have improved and 3-year 
patient survival can now exceed 75%. 5-year mortality of patients transplanted for ALF in the 
UK and US is 34.1% and 29.1% respectively, versus rates of 27.1% and 28.3% for those 
transplanted for CLD
36
. Patients transplanted for APAP and viral related ALF have better 
post-transplant outcomes than those transplanted for AIH and DILI-ALF
2
.  
The recent UK Liver Transplant Audit
37
 identified factors associated with increased risk of 
post-transplant mortality. These included older age of recipient, recipient ethnicity, 
requirement for pre-transplant renal support and the use of segmental/’split’ grafts. High 
donor BMI is a predictor of recipient death post-transplant, presumably related to graft 
steatosis. Other potential risk factors for post-operative mortality or graft loss include donor 
age >60, male gender and the use of an ABO incompatible graft
35
. Recipient BMI and lowest 
recipient pH prior to transplantation have also been shown to be associated with poorer 
outcome post-transplantation
38
.   
Over the preceding years, there has been increasing use of so called ‘marginal donors’ and 
alternative forms of liver transplantation to increase the donor pool for those listed for 
emergency OLT. ABO incompatible grafts have been used the setting of ALF with less 
favourable outcomes; 1-year survival is between 30 and 60%
39
 with ABO mismatching an 
independent risk factor for graft loss and death at 3 and 12 months
35
. 
Auxiliary liver grafting has been proposed as a temporising measure, either till native liver 
function recovers or formal transplantation occurs. This technique retains recipient liver and 
uses a partial right or left lobe of donor liver graft as a means of providing temporary liver 
support. Once native liver recovery occurs immunosuppression can be withdrawn with 
resultant shrinkage of the donor liver; this typically occurs within 1 to 3 years post OLT in 
70% of patients
34
.
 
Survival rates following auxiliary transplant have been reported to be 60-
65%
40
. Experience of this transplant option is limited, accounting for only 2% of liver 
transplants in Europe between 1999 and 2009
35
, but this remains an exciting and attractive 
option worthy of further exploration as it negates the need for long term immunosuppression. 
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Living donor liver transplant (LDLT) may reduce waiting times for those patients with ALF 
who require an organ urgently, and is of particular importance in certain areas of the world. 
In Japan, more than 98% of patients transplanted for ALF underwent LDLT
41
. Interestingly, 
the median time to transplant from the onset of encephalopathy was 4 days, compared with 1 
day in the US taking into account all donor types. One-year survival following adult to adult 
LDLT for all etiologies in the US was 81%
42
. In Japan, 1-, 5- and 10-year survival rates 
following LDLT for ALF are 79%, 74% and 73% respectively
43
. One major issue with the 
use of LDLT is the need for rapid yet thorough donor evaluation. One American group 
reported the outcomes of seven patients undergoing LDLT for ALF
44
. Donor work up was 
expedited and completed in a median of 24 hours. There was no significant difference in 
patients undergoing live or deceased donor transplantation in terms of post-operative 
complications, 1-, 3- and 5-year graft and patient survival. No severe donor complications 
were reported. LDLT may be a viable option to meet organ demand if the assessment process 
can be expedited with the process remaining thorough and complete without donor coercion. 
Larger studies with long-term follow up periods are required before this practice is more 
widely adopted.  
There is limited experience of the use of donation after cardiac death (DCD) grafts in patients 
with ALF. In the US, the number of DCD transplants performed for all indications has 
steadily increased over time; however data suggest inferior liver graft survival for organs 
retrieved from DCD donors versus DBD (donation after brain death) donors in a cohort of 
patients including those with ALF
45
. 
Longer term outcomes following spontaneous survival of ALF 
In ALF, the presumption is that if the patient is supported long enough, the liver is capable of 
complete regeneration and the patient returns to normal health with no long-term adverse 
health sequelae. However, recent studies have challenged this presumption. Studies from the 
USA and Denmark suggest that survival and quality of life of patients recovering 
spontaneously from ALF are reduced compared with the general population or liver 
transplant recipients
46-48
.  
Long term health care outcomes following liver transplantation for ALF 
The available data would suggest that quality of life is worse in those transplanted for ALF 
(in particular APAP-ALF) compared with those transplanted for CLD and hepatocellular 
carcinoma
49
. In the transplanted APAP-ALF cohort, there are later problems with 
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psychosocial morbidity, medication compliance and clinic attendance. Anxiety symptoms 
have been reported in 33.2% and depression in 16.7% of APAP-ALF transplanted patients 
with ongoing social/psychiatric issues in 35%
49, 50
. The incidence of psychiatric disease and 
30-day mortality is increased in patients with APAP-ALF compared with non-APAP ALF 
and CLD
51
. In addition, adherence to follow up and compliance with immunosuppression is 
reduced in the APAP-ALF group.  These social problems translate into a 10 times higher 
incidence of death and graft failure in the APAP-ALF cohort compared with other 
etiologies
35
. A higher incidence of suicide in the APAP-ALF group occurs, with 57% of 
suicides within 12 months of transplantation
35
. These data highlight the difficulty in 
identifying suitable patients for OLT and developing health-care structures to provide longer-
term support, particularly in the APAP cohort. Larger scale, long-term studies are necessary 
to investigate health care utilisation and outcomes in survivors of ALF (with and without 
transplantation), and to ensure the health care needs of this cohort are met. 
Alternatives to transplant 
Alternatives to liver transplant are urgently needed to fill the worldwide gap between supply 
and demand for donated organs. Potential alternatives include liver support systems, cell 
transplantation and liver tissue engineering, and such alternatives to transplant should be a 
major ‘future direction’ in managing the patient with ALF.  This is a highly specialised, 
rapidly developing field, with several recently published reviews
52-54
. Potential alternative to 
transplantation are discussed individually in the supplementary text. 
Future Directions and Conclusions 
There is little doubt that earlier recognition of ALF and improvements in medical and 
intensive care management have improved outcomes for patients with ALF. Whilst the donor 
organ pool is currently limited, attempts are being made to expand the pool by utilising 
marginal donors and alternatives such as auxiliary and living donor transplant. A recent paper 
by Bernal
55
 posed the question could ALF be a curable disease by 2024? To achieve this lofty 
goal, a number of factors need to be addressed in the next 10 years. Initially, a universally 
accepted definition of ALF must be established, to facilitate consistent and standardized 
research and clinical management of these patients. Further study of the pathogenesis and 
trajectory of disease is required to accurately and promptly define individual patient 
outcomes and identify new therapeutic targets with the aim of reducing the percentage of 
these patients who require emergency OLT. Furthermore, developments in the alternatives to 
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liver transplantation have the potential to limit the need for emergency liver transplantation 
and redirect donated organs for patients with chronic liver disease and cancer.  
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Table 1. UK registration criteria for super-urgent liver transplantation 
 
CATEGORY ETIOLOGY CRITERIA 
1 Acetaminophen pH<7.25 more than 24 hours 
after overdose and after fluid 
resuscitation  
2 Acetaminophen Co-existing PT>100 seconds 
or INR>6.5 and serum 
creatinine >300umol/L or 
anuria, and grade 3-4 
encephalopathy 
3 Acetaminophen Significant liver injury and 
coagulopathy following 
exclusion of other causes of 
hyperlactatemia after 
adequate fluid resuscitation: 
arterial lactate >5mmol/L on 
admission and >4mmol/L 24 
hours later in presence of 
clinical HE 
4 Acetaminophen 2 of the 3 criteria from 
category 2 with clinical 
evidence of deterioration (e.g. 
increased ICP, FiO2 >50%, 
increasing inotrope 
requirements) in the absence 
of clinical sepsis 
5 Favorable non-
acetaminophen 
(e.g. viral hepatitis, cocaine) 
The presence of clinical HE 
is mandatory and: PT>100 
seconds or INR >6.5, or any 
3 from the following: age>40 
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or <10 years; PT>50 seconds 
or INR >3.5; any grade of HE 
with jaundice to 
encephalopathy time >7 days, 
serum bilirubin >300umol/L  
6 Unfavorable non-
acetaminophen 
(e.g. indeterminate ALF, 
DILI) 
a) PT >100 seconds or 
INR>6.5 or b) in the absence 
of HE then INR >2 after 
vitamin K repletion is 
mandatory and any 2 from 
the following: age >40 or <10 
years; PT >50 seconds or 
INR>3.5; if HE is present the 
jaundice to encephalopathy 
time >7 days; serum bilirubin 
>300umol/L 
7 Acute Wilson disease or 
Budd-Chiari syndrome 
A combination of 
coagulopathy and any grade 
of encephalopathy 
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SUPPLEMENTAL MATERIAL 
 
Non-transplant management options of individual conditions. 
Ischemic hepatitis 
In ischemic or hypoxic hepatitis, the cornerstone of management is cardiovascular support 
and resuscitative measures. OLT is rarely indicated in ischemic hepatitis, or indeed feasible 
in view of the frequent presence of significant cardiorespiratory co-morbidity with high 
frequency of death from multiorgan failure reported
1
. In critically ill patients with ischemic 
hepatitis, statin therapy prior to critical care admission may be protective
2
.   
Pregnancy-related ALF 
ALF occurring during pregnancy as a result of AFLP or HELLP syndrome (hemolysis, 
elevated liver enzymes, low platelets) requires early delivery of the fetus, with good 
outcomes reported following delivery
3, 4
. However, postpartum deterioration can occur and 
transplantation may still be required if the liver failure does not resolve promptly after 
delivery
3
. Specifically in AFLP, it has been suggested that transplantation should be reserved 
for those with hepatic rupture complicated by necrosis, HE, severe metabolic acidosis and 
worsening coagulopathy
5
.    
Viral hepatitis 
For patients with ALF secondary to hepatitis B, treatment with nucleos(t)ide analogues 
should be considered. However, evidence of efficacy is equivocal
6
. Emerging data suggests 
ribavirin treatment is effective in cases of acute HEV infection
7
. Rarely, ALF may be caused 
by other viruses such as herpes virus or varicella zoster, and treatment with IV acyclovir 
should be started immediately
8
.  
Wilson Disease 
ALF due to Wilson disease is considered universally fatal and emergency OLT is the only 
proven therapeutic option for this disease process, even though liver cirrhosis is present. In 
those without HE, treatment with penicillamine or trientine may be tried in the first instance
9
.  
Autoimmune Hepatitis 
In patients with severe ALI due to autoimmune hepatitis (AIH) the decision regarding steroid 
therapy can be challenging, balancing the potential for recovery with the risk of sepsis in 
patients already with increased risk of infection.  Ichai described 16 patients presenting with 
acute, severe or fulminant AIH, in whom 10 cases proceeded to transplantation despite 
steroid treatment
10
. Severe septic complications were noted in three treated patients. More 
Page 21 of 40
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
recently a retrospective study
11
 identified a subset of patients with AIH-ALF with an initial 
MELD <27 and low grade HE that benefited from corticosteroids, an observation in keeping 
with AASLD recommendations
3
. Steroid use should therefore be avoided in AIH-ALF with 
advanced HE due to the risk of sepsis, worsening clinical condition and delay in 
consideration of OLT.  
DILI 
Steroids may also have a role in the management of DILI, in particular in cases where drug 
hypersensitivity such as the ‘drug rash with eosinophilia and systemic symptoms’ (DRESS) 
syndrome or an autoimmune reaction is implicated
12
.  
Budd-Chiari Syndrome 
ALF due to Budd-Chiari syndrome can respond to venous decompression via transjugular 
intra-hepatic portosystemic shunt (TIPSS) or hepatic vein stenting
13
, suggesting that OLT 
should be considered only in those patients who cannot be managed by TIPSS. Larger and 
longer term studies are required to clarify the best algorithm for the management of fulminant 
presentations of Budd-Chiari syndrome.  
Alcoholic hepatitis 
Alcoholic hepatitis is not usually considered a form of ALF, although when severe many 
features are similar, and there are few evidence-based medical therapies available. Early liver 
transplantation for severe alcoholic hepatitis remains a controversial issue. In a small group 
of patients (n=26) who were non-responders to steroids as assessed by the Lille score, early 
liver transplantation was associated with a significantly higher 6-month survival rate, and this 
benefit was maintained through 2 years of follow up
14
. Three of these patients returned to 
drinking alcohol. Reluctance to adopt this approach more widely relates to fears over harmful 
alcoholic recidivism, the fact that patients have not demonstrated their ability to gain control 
over their disease, and public perception that these patients may be less deserving of a 
transplant than other patients
15
.  
 
Development of infection and the Systemic Inflammatory Response Syndrome (SIRS)  
Developing infection and/or a SIRS response (two or more of: temperature <36⁰C or >38⁰C, 
heart rate >90 beats/min, respiratory rate >20 breaths/min or PaCO2 <4.3kPa and leucocyte 
count <4x10
9
/L or >12x10
9
/L) and resultant multi-organ failure limit hepatic regeneration 
and reduce survival. However, no survival benefit has been shown with the use of 
prophylactic antimicrobials in ALF
16, 17
. The AASLD Position Paper
3
 recommends that 
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periodic surveillance cultures are taken to identify infection early and that antibiotic 
treatment should be commenced at the earliest sign of active infection or deterioration, 
defined as progression to high grade HE or elements of SIRS.  
Active infection can be difficult to diagnose as a SIRS response is frequently associated with 
ALF without infection. Rolando initially reported the frequent presence of SIRS in patients 
with ALF secondary to a variety of etiologies
17
. Overall 58.6% of patients developed a SIRS 
response and even in the absence of infection SIRS on admission was associated with a more 
critical illness, subsequent worsening of HE and death. These data have been reproduced by a 
number of different groups
16, 18
. Associated with the SIRS, a compensatory anti-inflammatory 
response syndrome (CARS) has also been implicated in the pathogenesis of multiorgan 
failure in ALF
19
. CARS is defined by persistently elevated levels of anti-inflammatory 
cytokines and impairment in cellular immune function. A pathological CARS has been 
reported in patients with ALF, characterised by excessive immunosuppression, functional 
monocyte deactivation, and increased predisposition to infection. Understanding the 
pathogenesis of SIRS and CARS in ALF might lead to novel therapies that reduce or prevent 
the high mortality related to infection in this condition. 
Assessing prognosis and listing for transplant 
The KCC were initially proposed by O’Grady in 1989 and were derived from a cohort of 
almost 600 patients
20
. All patients had Grade 3 or 4 HE, representing the most severe cases of 
ALF. These criteria differentiated between APAP and non-APAP etiologies. The KCC have 
been consistently shown to have a high degree of specificity, but a reduced sensitivity
21, 22, 23
 
(Supplementary Table 1). The KCC for APAP were later updated to include arterial lactate. 
Bernal
24
 measured arterial blood lactate early and after fluid resuscitation in patients with 
APAP-ALF. Combined early and post-resuscitative lactate concentrations had similar 
predictive ability to standard KCC, but identified non-survivors earlier in their clinical 
course. Importantly with the observed increase in staggered APAP overdose in the UK is the 
observation that the KCC has reduced sensitivity in predicting outcome in this type of 
overdose pattern compared with single time point overdose (77.6% versus 89.9% 
respectively)
25
. A recent systematic review identified that the original KCC for APAP-ALF 
had a pooled sensitivity of 58.2% and specificity of 94.6% with a diagnostic odds ratio 
(DOR) of 27.7
21
. DOR is a measure of effectiveness of a test, defined as the ratio of the odds 
of the test being positive if the subject has the disease relative to the odds of the test being 
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positive if the subject does not have the disease; a large DOR is indicative of good test 
performance. In the UK, the criteria for listing patients with APAP-ALF for emergency OLT 
on the basis of arterial lactate has also recently been reviewed and modified
26
. Patients with 
APAP-ALF are now listed for OLT on the basis of both an arterial lactate >5mmol/L on 
admission and >4mmol/L 24 hours later in the presence of clinical HE.  
McPhail
22
 performed a meta-analysis of the performance of the KCC in predicting outcomes 
of patients with non-APAP ALF. Summary sensitivity was 68% with a specificity of 82% 
and DOR of 12.6. Importantly, this study identified that sensitivity was reduced in studies 
published later than 1995 (58%) compared with studies published earlier than 1995 (85%), 
with an associated fall in DOR over time. These results suggest that the performance of the 
KCC has deteriorated over time, at least in the non-APAP cohort, and that as the trajectory of 
the clinical course of the ALF patient is changing, the criteria need updating and further 
validation studies undertaken. 
The Clichy criteria
27
 were developed in France and are used predominantly in Northern 
Europe. These criteria were derived from a cohort of patients with ALF secondary to hepatitis 
B, and therefore may not be applicable to patients with non-viral etiologies. This scoring 
system is based upon the presence of HE and Factor V levels. Factor V measurement is not 
available in many countries, again limiting general application of these criteria. Yantorno 
reported that in adult patients with ALF, the Clichy criteria had a better positive predictive 
value (PPV) compared with KCC (87% versus 65% respectively), but a lower negative 
predictive value (67% versus 83% respectively)
28
. More recently Ichai has identified that the 
performance of the Clichy criteria could be improved if APAP-ALF and non-APAP ALF 
were differentiated, and if serum bilirubin and creatinine clearance were incorporated
29
. 
Unfortunately, as currently applied the Clichy criteria appear to have a limited prognostic 
capacity.  
MELD was designed to estimate post-procedural mortality in cirrhotic patients undergoing 
TIPSS and has been widely evaluated in predicting mortality in those with chronic liver 
disease. Several studies have investigated the predictive power of MELD in patients with 
ALF. Kremers observed survival was negatively correlated with MELD in patients with non-
APAP ALF
30
. Others have reported a MELD score >35 predicted mortality with a sensitivity 
of 86% and specificity of 75% in non-APAP ALF
31
. In APAP-ALF MELD was significantly 
higher in patients with HE, but did not perform any better than the KCC in predicting death
32
. 
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In a direct comparison of the prognostic accuracy of KCC, Clichy and MELD in adults with 
ALF, MELD was superior
28
. However, the authors recognised that this was a single center 
study with limited numbers and the most frequent cause of ALF was AIH; therefore the 
reported utility of MELD may not be generally applicable to other populations and further 
studies are required.  
The role and utility of the widely used prognostic scoring systems may differ according to 
etiology of ALF. A recent meta-analysis identified that KCC more accurately predicted 
hospital mortality in APAP-ALF, whereas MELD more accurately predicted mortality in 
non-APAP ALF
33
. Within APAP-ALF, the performance of the KCC appears to vary with 
overdose pattern
25
. A few disease specific prognostic models for etiologies other than APAP 
poisoning have been reported, but generally have yet to be validated in larger and alternative 
ALF cohorts.  
Several new scoring systems and prognostic biomarkers have been described, including the 
use of CT liver volume
34, 35
 and thyroid hormone levels
36
. (Supplementary Table 2
23, 34-43
). 
However, a systematic review of new models highlighted methodological and reporting 
limitations
44
. New prognostic models with high sensitivity and specificity are urgently 
needed. Increasing the sensitivity of prognostic scoring systems favours the individual 
patient, and improving the specificity would allowing targeting of limited organs to those 
most likely to benefit. The ideal prognostic model should be highly sensitive and specific, 
with ease and rapidity of clinical application. The prognostic marker or scoring system 
should utilize readily available validated variables that could be dynamically applied to 
reflect the speed with which the clinical condition can evolve. Further multicenter studies 
assessing new scoring systems and adapting current prognostic systems with newly identified 
biomarkers are urgently required. 
Development and Management of Cerebral Edema (CE) 
 
CE is one of the most devastating complications of ALF as it may lead to the development of 
intracranial hypertension (ICH) and death. CE is rarely reported in patients with chronic liver 
disease, even in those with acute decompensation or acute on chronic liver failure. Up to 25% 
of ALF patients will develop CE, with CE occurring in up to 80% of patients with grade IV 
HE
45
. It was recently reported that the proportion of patients with ICH fell from 76% in 1984-
1988 to 20% in 2004-2008, with 50% reduction in associated mortality
46
. Evolution of 
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therapies over the years such as use of NAC, antibiotic therapy and CVVH and earlier patient 
presentation were speculated to have modified potential factors in the pathogenesis of ICH. 
The pathophysiology of CE in ALF is complex but now more completely understood
47
 
occurring as a consequence of vasodilatation of cerebral arterioles and neuroinflammation 
from a direct interaction between microglia and ammonia. An impaired urea cycle as a result 
of hepatocyte loss results in rising blood ammonia concentration. Hyperammonemia causes 
increased synthesis and accumulation of glutamine in astrocytes and cellular swelling. 
Arterial ammonia concentration is an independent risk factor for the development of higher 
grade HE and ICH, with an ammonia level >100umol/L predicting the onset of severe HE 
with 70% accuracy
48
. Elevated arterial ammonia is also associated with a greater likelihood 
of death from brain herniation
49
.  
Reductions in cerebral perfusion pressure (CPP) are associated with a high risk of ischemic 
brain injury. ICP monitoring allows earlier detection and management of elevated ICP and 
assists decision making. However, ICP monitoring has recognized complications. The risk of 
intracranial hemorrhage is significant and can lead to disability and death. A previous study 
from the United States reported bleeding in 21% of cases
50
. More recently the outcomes of 
those undergoing ICP monitoring in 25 US centers have been reported
51
. Of a sub-group of 
58 patients Vaquero described a 10% complication rate, all related to intracranial 
hemorrhage. In those listed for OLT and managed with ICP monitoring, the 30-day survival 
rate post-transplant was not significantly different between the monitored and un-monitored 
group. No information was available on the long-term neurological recovery of these patients 
and this is a field worthy of further exploration. Transcranial Doppler ultrasound is an 
alternative non-invasive method of monitoring cerebral hemodynamics, with limited studies 
assessing utility in ALF
52, 53
. There is no worldwide agreement on the best practice in ICP 
monitoring and treatment of CE, however the AASLD practice guidelines for ALF
3, 54
 advise 
that ICP monitoring should be utilized in patients with high grade HE, in centres with 
experience in ICP monitoring and in patients who are awaiting and undergoing OLT. This is 
another area worthy of future research. 
 
Osmotic therapy with mannitol is recommended as first line therapy for raised ICP, having 
been shown in small studies to correct discrete episodes in patients with ALF
54, 55
. Induced 
hypernatremia (serum sodium 145-155umol/L) with hypertonic saline has also been shown to 
be effective
56
. Short acting barbiturates, therapeutic hypothermia (TH) and indomethacin are 
utilized as second-line measures to control ICP. In animal models of ALF, TH has been 
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shown to prevent development of CE
57
. However, a recent multicenter retrospective cohort 
analysis reported that TH did not have a significant effect on 21-day survival or transplant-
free survival in humans
58
. In this study, TH was not associated with increased bleeding risk 
or infection. Further prospective studies would be useful to clarify if TH could have a role in 
the management of patients with ALF, particularly for those who are deemed to be at high 
risk of developing CE whilst on the transplant waiting list, such as the young and those with 
APAP-ALF.  
Ammonia is a key contributor in the pathogenesis of HE and ICH in ALF. Therapies directed 
at reducing or clearing ammonia could potentially reduce HE and prevent ICH.  
Plasmapheresis decreases arterial ammonia and may have effects on systemic immune and 
endothelial dysfunction by reducing the pro-inflammatory milieu
59
. Plasmapheresis in ALF 
has demonstrated improvements in HE and hemodynamic parameters, but with no definitive 
effect on survival
60
. However, a recent randomized controlled trial investigated high-volume 
plasma exchange (HVP) in patients with ALF; overall hospital survival was higher in those 
treated with HVP versus the control group (58.7% versus 47.8%), and the authors postulated 
that improved survival was as a result of effects on immune activation and multi-organ 
dysfunction
61
. CVVH has also been proposed as a method of reducing circulating ammonia 
concentrations, with one study including patients with ALF reporting a 22% reduction in 
mean arterial ammonia concentration over 24 hours of CVVH
62
. L-ornithine L-aspartate 
(LOLA) can also reduce circulating ammonia concentrations by increasing hepatic ammonia 
disposal and peripheral metabolism. However, a double-blind, randomized, placebo 
controlled trial reported that LOLA infusion did not lower ammonia or improve survival in 
ALF 
63
.  
 
Alternatives to Transplant 
Liver support systems  
Extra-corporeal liver assist devices (biological and non-biological) remain largely 
experimental. Biological liver support systems incorporate living liver cells into a device with 
the aim of allowing both detoxification and hepatic synthetic functions. The HepatAssist 
(Alliqua Inc, Langhorne, PA, USA) system is perhaps the best known biological device and 
utilizes porcine hepatocytes within a dialysis cartridge. In a prospective, randomized 
controlled multicenter trial of the HepatAssist in patients with ALF and primary non-function 
there was a trend towards increasing survival in the device treated group
64
. When analyzed 
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for confounding factors, survival in the group of patients with ALF was significantly higher 
in the HepatAssist treated group compared with controls. The Extracorporeal Liver Assist 
Device (ELAD) utilizes cells derived from a human hepatoblastoma cell line. A clinical pilot 
controlled study of this system demonstrated a slightly higher rate of improvement in HE 
after 6 hours of treatment in the ELAD group, however no significant survival benefit was 
demonstrated
65
. 
Non-biological liver support systems facilitate removal of toxins not cleared by the non-
functioning liver, but do not replace the synthetic function of the liver as they do not contain 
any living cells. The Molecular Adsorbent Recirculating System (MARS, Gambro Americas, 
Lakewood, CO) and Plasma Separation Adsorption and Dialysis system (Prometheus, 
Fresenius Medical Care, Bad Homburg, Germany) have been the most frequently studied 
non-biological systems. However, no non-biological device has been demonstrated to reduce 
mortality in ALF, and further developmental work is required
66, 67
.  
A systematic review evaluating the effect of biological and non-biological support systems in 
ALF and acute on chronic liver failure reported that non-biological support systems reduced 
mortality in acute on chronic liver failure, however neither biological nor non-biological 
systems impacted upon mortality in ALF
68
. A further systematic review and meta-analysis 
looking at survival following extracorporeal liver support (biological and non-biological) 
found that these systems significantly improved survival in ALF with a number needed to 
treat of 8, whereas no significant survival benefit was seen in patients with acute on chronic 
liver disease
69
. The data with regards to liver support systems are therefore conflicting and 
larger scale studies following further developmental work are urgently needed.  
Cell Therapy: Hepatocyte transplantation 
Hepatocyte transplantation aims to repopulate the liver with functional donor hepatocytes, 
injected either directly into the liver, or into the spleen from where they can migrate to the 
liver. Hepatocytes for transplantation are usually prepared from donor liver tissue not used 
for transplantation, and may therefore represent marginal graft tissue. In animal models of 
ALF, hepatocyte transplantation can improve survival
70, 71
. Translation of this apparent 
benefit to humans has been hampered by the availability of functional human hepatocytes and 
difficulty in resuscitating the cells following cryopreservation. A few pediatric case reports 
exist
72
 but further research and technological advances are required before hepatocyte 
transplantation for ALF can be adopted into clinical practice in adults. 
Cell Therapy: Stem cell therapy  
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Stem cells or stem cell derived hepatocytes are one potential solution to the shortage of viable 
hepatocytes. Ramanathan investigated the effect of stem cell derived hepatocyte-like cells in 
an animal model of ALF
71
. In rats transplanted with these cells, increased survival rates were 
observed along with evidence of albumin production. One of the main limitations of stem cell 
therapy in humans is the limited cell survival post-transplant. This may be related to 
insufficient resistance of the transplanted cells to oxidative and inflammatory stressors
73
. 
Stem cell therapy for ALF is certainly worthy of further investigation and hopefully in due 
course translation into therapy for human ALF.  
Liver Tissue Engineering and Bioprinting 
Bioengineering methods have been developed that allow for maintenance of the anatomical 
structure of an organ such as the liver and allow repopulation with hepatic cells which can 
form physiological contacts. 3D bioprinting is a recent advance in tissue engineering that 
allows construction of parenchymal organ structures, and raises the possibility of being able 
to print a functional artificial liver. 3D organ printing uses biofabrication techniques to build 
3D spheroids via a layered approach. Robbins
74
 introduced 3D hepatic tissue along with a 
primitive microanatomy of stellate cells and endothelial cells using the NovoGen MMX 
Bioprinter, with liver specific metabolic function lasting up to 135 hours. This technique is 
still in its infancy, but is an exciting development in its field.  
Stimulation of Regeneration 
Liver regeneration following injury plays a vital role in determining patient outcome, 
particularly with regards to APAP-induced liver injury. Timely stimulation of liver 
regeneration with factors such as vascular endothelial growth factor improves survival 
following APAP overdose in mice
75
.  The role of macrophage colony stimulating factor 
(CSF1) in liver regeneration has also been studied
76
. In patients with APAP-ALF, low levels 
of CSF1 were associated with increased mortality, and in mice, administration of CSF1 
promoted hepatic macrophage accumulation. CSF1 may be a new therapeutic target in ALF. 
Further human studies are urgently required to identify signalling pathways involved in liver 
regeneration, which may provide a new therapeutic target for the patient with ALF. 
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SUPPLEMENTAL TABLES. 
 
Supplemental Table 1. Summary of recent systematic review and studies assessing utility of KCC 
 
 ETIOLOGY SENSITIVITY  SPECIFICITY POOLED 
DOR 
AUC 
Craig21  
Systematic 
review 
APAP-ALF 58.2% 
(95% CI 53.1-63.3) 
94.6% 
(95% CI 93.0-95.9) 
27.7 
(95% CI 
9.2-83.5) 
0.91 
(95% CI 
0.79-0.99) 
McPhail22 
Meta-analysis 
Non-APAP ALF 68% 
(95% CI 59-77) 
82% 
(95% CI 75-88) 
12.6 
(95% CI 
6.5-26.1) 
- 
Cholongitas
23
  
Retrospective 
analysis 
APAP-ALF 47% 83% - 0.65 
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Supplemental Table 2. Alternative scoring systems and biomarkers in ALF 
 
Model/marker Study Outcome 
SOFA Cholangitas
23 
Performed better in predicting prognosis than KCC/MELD in APAP-ALF (SOFA AUC 0.79, 
KCC AUC 0.65) 
 Craig
37 
Score > 7 during first 96 hours in APAP-ALF predictive of death/transplant (sensitivity 95%, 
specificity 76.9%) 
Gc-Globulin Schiodt
38 
Gc-Globulin levels significantly higher in ALF spontaneous survivors versus those who 
died/were transplanted (p 0.002) 
 Antoniades
39 
Gc-Globulin levels significantly higher in ALF spontaneous survivors versus those who 
died/were transplanted (p 0.01) 
M-30 Rutherford
40 
(ALFSG) 
ALFSG index (including log10M-30) (AUC 0.822) better at identifying patients likely to die/be 
transplanted than KCC (AUC 0.654) or MELD (AUC 0.704) 
 Possamai
41 
Admission M30 levels significantly higher in ALF patients versus CLD and normal controls. 
Admission levels correlate with outcome (AUC 0.755) 
 Craig
42 
Did not improve prognostication beyond KCC in APAP-ALF 
Thyroid 
hormone 
Anastasiou
36 
Significantly higher TSH, T4 and T3 levels in ALF spontaneous survivors versus those who 
died/underwent transplantation 
CT liver volume Yamagishi
34 
CT-measured Estimated Liver Volume/Standard Liver Volume higher on day 0 and 5 in ALF 
survivors compared with those who died or underwent transplantation 
 Shakil35 CT liver volume <1000mls and/or parenchymal necrosis >50% indicative of a poor prognosis 
 Yamagishi
43 
CT liver volume (CTLV)/standard liver volume (SLV) ratio <0.80 had a 75.6% sensitivity and 
92.3% specificity for death 
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